POAG

PSLT shows promise in lowering intraocular pressure Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.
SLT valuable tool in individualized approach for glaucoma managementWhen customizing treatment plans for glaucoma patients, selective laser trabeculoplasty (SLT) can be as useful in diagnosis as it is in reducing IOP, explains Inder Paul Singh, MD, FEBOphth.
Engaging OCTA in glaucoma imaging
Engaging OCTA in glaucoma imagingA prospective, observational study found that eyes with mild POAG could be differentiated from pre-perimetric glaucomatous eyes, which also could be differentiated from normal eyes using OCTA-derived retinal vessel density measurements.
Poor oral health may be associated with POAG
Poor oral health may be associated with POAGRecent tooth loss and periodontal disease have been linked to primary open-angle glaucoma in a large prospective study of male health professionals.
New technology predicts conversion to POAGClinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Microstent approval makes big news in glaucoma world
Microstent approval makes big news in glaucoma worldClinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
Novel gelatin stent works effectively as stand-alone procedureOne-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma.
Santen to acquire InnFocus, developer of glaucoma drainage implantSanten Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.
How 24-hour IOP measurements vary with glaucoma treatmentClinicians should take into account the way IOP varies over the course of 24 hours depending on the glaucoma treatment used, according to the authors of a new literature review.
MICS & MIGS: combined surgery with microstent devicesThe combination of MICS and MIGS can offer an effective surgical treatment for POAG when the reduction of IOP following cataract surgery alone is not sufficient to reduce a patient’s need for glaucoma therapies.